An intelligent search tool for clinical trials

Sign In
Back|NCT06876649Recruiting
Official Title

A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib

Phase
Phase 4
Sponsor
Eli Lilly and Company
Enrollment
787
Timeline
May 2025 → Dec 2032
About This Study

The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the opportunity to enter this study and continue to receive treatment or continue follow-up visits. Overall, the master protocol and the individual ISAs, when combined, define the investigations for this study.

Eligibility Criteria

Inclusion Criteria

  • 1Are participating in an eligible Lilly sponsored clinical study evaluating pirtobrutinib.

Locations

38 sites participating in this study

The Emory Clinic

Atlanta, Georgia 30322-1013

Recruiting

Jonathon Cohen

Cancer Specialists, LLC

Jacksonville, Florida 32256

Recruiting

Ayed Ayed

Sylvester Comprehensive Cancer Center

Miami, Florida 33136-1002

Recruiting

Alvaro Alencar

Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →